Literature DB >> 27798205

Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study.

Sofia Ny1,2, Sonja Löfmark1, Stefan Börjesson3, Stina Englund3, Maj Ringman1, Jakob Bergström1, Pontus Nauclér4,5, Christian G Giske6,7, Sara Byfors1.   

Abstract

OBJECTIVES: Community carriage of ESBL-producing Escherichia coli (EPE) is common worldwide and there is a need to understand the connection between carriage and infection. We compared the molecular characteristics of EPE among Swedish community carriers with those of EPE causing invasive infections.
METHODS: We collected 2134 faecal samples from randomly selected Swedish inhabitants and examined them for the presence of EPE. All participating volunteers answered a questionnaire about putative risk factors for EPE carriage. Suspected EPE isolates (n = 418) from patients with bloodstream infection (BSI) were collected from Swedish laboratories. Isolates were genotypically and phenotypically characterized.
RESULTS: Our results show that the EPE population found in carriers generally had lower pathogenicity compared with the isolates from BSIs, since carriers had a lower proportion of E. coli belonging to phylogroup B2, ST131 and ST131 subclone H30-Rx. Isolates from carriers also had lower levels of multiresistance. The Swedish carriage rate of EPE was 4.7% (101/2134) among healthy volunteers. Risk factors associated with carriage were travel to countries in Asia (OR = 3.6, 95% CI = 1.4-9.2) and Africa (OR = 3.6, 95% CI = 1.7-7.7) and a diet without pork (OR = 0.5, 95% CI = 0.3-0.8 for pork eaters).
CONCLUSIONS: E. coli host factors previously associated with higher pathogenicity were all more common in BSIs compared with carriers. This indicates that the risk of invasive infection with EPE may be relatively modest in many community carriers and that EPE carriage of high-risk strains should be the focus of attention for prevention.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27798205     DOI: 10.1093/jac/dkw419

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  Subsequent infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in patients with prior infection or fecal colonization.

Authors:  Anna Lindblom; Nahid Karami; Tim Magnusson; Christina Åhrén
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-23       Impact factor: 3.267

2.  Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia.

Authors:  Sofia Ny; Roman Kozlov; Uga Dumpis; Petra Edquist; Kirsi Gröndahl-Yli-Hannuksela; Anna-Maria Kling; Danuta O Lis; Christoph Lübbert; Monika Pomorska-Wesołowska; Ivan Palagin; Aija Vilde; Jaana Vuopio; Jan Walter; Karin Tegmark Wisell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-10-18       Impact factor: 3.267

3.  Extended-Spectrum-β-Lactamase- and Plasmid AmpC-Producing Escherichia coli Causing Community-Onset Bloodstream Infection: Association of Bacterial Clones and Virulence Genes with Septic Shock, Source of Infection, and Recurrence.

Authors:  Inga Fröding; Badrul Hasan; Isak Sylvin; Maarten Coorens; Pontus Nauclér; Christian G Giske
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

4.  Evaluation of MLVA for epidemiological typing and outbreak detection of ESBL-producing Escherichia coli in Sweden.

Authors:  Lisa Helldal; Nahid Karami; Christina Welinder-Olsson; Edward R B Moore; Christina Åhren
Journal:  BMC Microbiol       Date:  2017-01-06       Impact factor: 3.605

5.  ESBL-producing Escherichia coli in Swedish gulls-A case of environmental pollution from humans?

Authors:  Clara Atterby; Stefan Börjesson; Sofia Ny; Josef D Järhult; Sara Byfors; Jonas Bonnedahl
Journal:  PLoS One       Date:  2017-12-28       Impact factor: 3.240

6.  High prevalence of ESBL-Producing E. coli in private and shared latrines in an informal urban settlement in Dar es Salaam, Tanzania.

Authors:  Stefan Erb; Lauren D'Mello-Guyett; Hamisi M Malebo; Robert M Njee; Fatuma Matwewe; Jeroen Ensink; Vladimira Hinic; Andreas Widmer; Reno Frei
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-06       Impact factor: 4.887

7.  Travel to Asia is a strong predictor for carriage of cephalosporin resistant E. coli and Klebsiella spp. but does not explain everything; prevalence study at a Norwegian hospital 2014-2016.

Authors:  Laura Espenhain; Silje Bakken Jørgensen; Truls Michael Leegaard; Michaela Marie Lelek; Siri Haug Hänsgen; Britt Nakstad; Marianne Sunde; Martin Steinbakk
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-29       Impact factor: 4.887

8.  Prevalence, risk factors and genetic characterisation of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the Netherlands, 2014 to 2016.

Authors:  Gerrita van den Bunt; Wilfrid van Pelt; Laura Hidalgo; Jelle Scharringa; Sabine C de Greeff; Anita C Schürch; Lapo Mughini-Gras; Marc J M Bonten; Ad C Fluit
Journal:  Euro Surveill       Date:  2019-10

9.  Molecular characterization, antimicrobial resistance and clinico-bioinformatics approaches to address the problem of extended-spectrum β-lactamase-producing Escherichia coli in western Saudi Arabia.

Authors:  Muhammad Yasir; Abeer M Ajlan; Shazi Shakil; Asif A Jiman-Fatani; Saad B Almasaudi; Muhammad Farman; Zainah M Baazeem; Rnda Baabdullah; Maha Alawi; Nabeela Al-Abdullah; Nashat A Ismaeel; Hani A Shukri; Esam I Azhar
Journal:  Sci Rep       Date:  2018-10-04       Impact factor: 4.379

10.  Duration of travel-associated faecal colonisation with ESBL-producing Enterobacteriaceae - A one year follow-up study.

Authors:  Åse ÖstholmBalkhed; Maria Tärnberg; Maud Nilsson; Lennart E Nilsson; Håkan Hanberger; Anita Hällgren
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.